VivoSeq
Other

Facial Paralysis

4

Pipeline Programs↗

1

Active Trials↗

2

Companies Involved↗

Facial Paralysis is an early-stage landscape with 4 programs across 2 companies. The most active players are Revance Therapeutics, Inc., Eisai. 1 therapy is approved.

Intelligence

Pipeline Metrics

Competitive Density

25/100

Pipeline Velocity

6/100

Mech. Concentration

100/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

R

Revance Therapeutics, Inc.

1 program

PreclinicalEisai logo

Eisai

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

5

clinical trials

Completed3 · 60%
Unknown status1 · 20%
Not yet recruiting1 · 20%

Clinical Trials

Trial Activity

Effect of Stellate Ganglion Block Combined With Facial Nerve Block on the Treatment of Idiopathic Facial Paralysis
Completed·—·N/A·NCT04800666·80 enrolled
Onabotulinumtoxin A and Hyaluronic Acid Fillers in the Treatment of Facial Paralysis
Unknown status·AAzienda Ospedaliera Universitaria Integrata Verona·Phase 2·NCT05012566·70 enrolled
Mixed Methods Investigation of Chronic Facial Paralysis in Individuals With Synkinesis
Completed·UUniversity of Wisconsin, Madison·Phase 4·NCT04148872·15 enrolled
Photobiomodulation Therapy for Idiopathic Facial Paralysis
Completed·—·N/A·NCT05585346·96 enrolled
Mindfulness in Nonflaccid Facial Paralysis
Not yet recruiting·WWake Forest University Health Sciences·Preclinical·NCT07127016·24 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)